BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing
BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.
BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing Read More »
